Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation
A six-month, double-blind trial randomized 50 adults with HIV receiving antiretroviral treatment. Imaging showed reductions in visceral and liver fat in the tesamorelin group compared with placebo.
Study limitations
This was a small, specific population. Imaging changes are not proof of general weight-loss benefit or long-term clinical outcomes. Early glucose changes were observed.
